LLY vs MMED
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
MMED presents a dichotomy between strong fundamental health and poor market performance. The Piotroski F-Score of 5/9 indicates a stable financial condition, supported by an exceptionally low Debt/Equity ratio of 0.02 and a healthy Current Ratio of 1.77. However, the stock is in a severe technical downtrend with a 0/100 trend score and consistent -22.2% returns over multiple time horizons. While analysts maintain a 'strong_buy' with a target of $22.45, the company's negative profit margin (-7.31%) and bearish insider sentiment (40/100) suggest significant headwinds before a recovery is realized.
Compare Another Pair
Related Comparisons
LLY vs MMED: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Minimed Group, Inc. (MMED) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.